Key tongue cancer companies driving the innovation and addressing the unmet needs in this therapeutic space include Modra Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Cipla Inc., Eli-Lilly, F. Hoffmann-La Roche, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., MERCK & CO. INC., VIATRIS INC., Sanofi S.A, Teva Pharmaceuticals Industries Ltd, GSK, Novartis, Pfizer and Orca...

Retinal pigment epithelium market is poised for notable growth, being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios, Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics,...

DelveInsight’s in-depth analysis highlights strong growth prospects for the PI3K inhibitors market across the 7MM through 2034. Leading companies such as Roche/Genentech (ITOVEBI), Novartis (PIQRAY), Gilead Sciences (ZYDELIG), Kazia Therapeutics (Paxalisib), and Celcuity (Gedatolisib) are driving this expansion, fueled by the increasing use of PI3K inhibitors in both hematological and...

The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).   DelveInsight’s “Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast – 2034” report delivers comprehensive...

The TNBC treatment market is poised for significant expansion, driven by the introduction of novel targeted therapies, immunotherapeutics, and antibody-drug conjugates by key players such as Merck, Roche, Gilead Sciences, AstraZeneca, Daiichi Sankyo, Seagen, Immunomedics, Novartis, BMS, Pfizer, and Eisai, among others.   DelveInsight’s “Triple-Negative Breast Cancer Market...

DelveInsight projects the Vitrectomy Devices market, valued at USD 1.12B in 2023, to grow at 7.12% CAGR through 2030, driven by rising retinal disorders and AI-enabled systems. Key players include Alcon, Carl Zeiss Meditec AG, Leica Microsystems, IRIDEX, Lumenis, NIDEK, D.O.R.C., Geuder, Optos, Hoya Surgical Optics, BVI, and Johnson & Johnson. North America leads, with regulatory shifts...

DelveInsight projects the global Drug Delivery Devices market to grow at a 7.90% CAGR through 2030, driven by rising chronic diseases and innovation in injectables, inhalers, implants, and patches. Key players include Pfizer, Johnson & Johnson, Roche, Novartis, 3M, Bayer, Boehringer Ingelheim, and Medtronic. Oncology, diabetes, and respiratory diseases fuel demand, with FDA’s QMSR set...

DelveInsight Business Research’s latest analysis highlights the significant impact of the FDA’s approval of Pfizer and BioNTech’s updated COMIRNATY LP.8.1-adapted monovalent COVID-19 vaccine on August 26, 2025. This landmark approval marks a strategic shift toward risk-based vaccination strategies, targeting the most vulnerable populations while addressing the evolving...

DelveInsight’s latest analysis highlights the transformative potential of Regeneron Pharmaceuticals’ positive Phase 3 NIMBLE trial results for cemdisiran in generalized myasthenia gravis (gMG). This landmark achievement marks a significant advancement in complement inhibition therapy, offering new hope for patients suffering from this chronic autoimmune neuromuscular disorder...

DelveInsight’s comprehensive Phenylketonuria Market Insight, Epidemiology and Market Forecast – 2034 report provides crucial intelligence for pharmaceutical companies, investors, and healthcare stakeholders navigating the evolving Phenylketonuria therapeutic landscape.   Key Takeaways and Recent Developments Phase 3 APHENITY Trial Data Reveal Robust Diet Liberalization: In...